Tag: management

Trim IQ UK And Ireland is a powerful weight loss Dietary Supplement management solution that targets fat, Garcinia & Green Tea Probiotic Complex curbs cravings, and supports healthy energy and focus and boost energy naturally.

Bragar Eagel & Squire, P.C. Litigation Attorneys Encourage Investors Who Suffered Losses In Tempus (TEM) To Contact Him Directly To Discuss Their Options

LONDON, Aug. 02, 2025 (GLOBE NEWSWIRE) -- TwentyOneVC, a financial business, has launched a new suite of trading tools to assist individual investors in making smarter financial decisions. The updates provide a more transparent market view, enhanced access to trading, and enhanced risk management to users who trade in forex, stocks, cryptocurrencies, indices, and commodities.

NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tungray Technologies Inc (NASDAQ: TRSG) resulting from allegations that Tungray Technologies may have issued materially misleading business information to the investing public.

SINGAPORE, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Ostium, a decentralized trading platform, has announced the launch of a new leveraged trading instrument: 0DTE perpetuals for equities. The instrument combines intraday expiry with perpetual structure, offering day traders up to 100x leverage on individual stocks during market hours — a structural innovation aimed at addressing the limitations of traditional options and CFDs.

Not for distribution to U.S. News wire services or dissemination in the U.S.

NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- The Boards of Trustees/Directors of the PIMCO closed-end funds below (each, a “Fund” and, collectively, the “Funds”) have declared a monthly distribution for each Fund’s common shares as summarized below.

DALLAS, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on August 1, 2025, the Compensation Committee of Taysha's Board of Directors granted one new employee an option to purchase 90,000 shares of the Company's common stock in connection with their employment. The stock option was granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individual entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).